Three new chemists have joined Contract Research and Development Organization Arcinova’s Active Pharmaceutical Ingredient (API) team.
Left to right: Stephen McQuaker, Martin Wilmshurst and Celia Brammah.
Arcinova, which is headquartered in Alnwick, UK, provides integrated end to end solutions and standalone services to pharmaceutical and biotech companies. The company has recruited synthetic chemists Stephen McQuaker and Celia Brammah, and API development chemist Martin Wilmshurst, as part of the ongoing expansion of its API services.
The company’s API services include process research, development and scale-up to multi-kg quantities, stable isotopic labelling, 14C radiolabelling, and metabolite and reference material synthesis. It can handle high potency and high hazard compounds.
Martin Wilmshurst, who specialises in scaling up and developing manufacturing processes for drug candidates, has a BA from The Queens College, Oxford, a PhD in Organic Chemistry from UCL, and undertook postdoctoral research at the Université de Versailles Saint-Quentin-en-Yvelines in France. Prior to joining Arcinova, he held principal chemist, GMP Team Leader and QA positions at a number of international companies working in drug development.
Celia Brammah, who holds an MChem in Chemistry from Durham University, joins Arcinova from Johnson Matthey, where she worked as a graduate scientist. Stephen McQuaker, who has a PhD in Organic Chemistry and Chemical Biology from The University of Glasgow, previously worked as a senior process development chemist at Hartlepool-based Frutarom and as an R&D formulation assistant at Reckitt Benckiser’s Hull facility.
“We are delighted to welcome Celia, Martin and Stephen to the Arcinova team,” Paul Quigley, head of API at Arcinova, said. “Their expertise will further boost the support we offer to pharma and biotech companies across the world and their appointments come at a time when we are seeing increased demand for our API-related services.”